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Introduction:  The  phase  III SATURN  study  demonstrated  that  ﬁrst-line  maintenance  erlotinib  extended
progression-free  survival  (PFS) and  overall  survival  (OS)  versus  placebo  in  patients  with  advanced  non-
small  cell  lung  cancer  (NSCLC).  Analysis  of epidermal  growth  factor  receptor  (EGFR)  expression  by
immunohistochemistry  (IHC)  found  no signiﬁcant  interaction  between  EGFR  IHC  status  and  PFS  (p = 0.63)
or  OS  (p = 0.52).  The  FLEX  study  of  ﬁrst-line  cetuximab  plus  chemotherapy  demonstrated  that  EGFR  IHC
expression  was  predictive  of improved  OS  with  cetuximab  when  assessed  by H-score  with  a  magniﬁcation
rule.  This  novel  method  was used  to reassess  samples  from  SATURN.
Methods: The  H-score  method  assigned  a  score  of  0–300  to each  patient,  based  on the  percentage  of  cells
stained  at  different  intensities  viewed  at various  magniﬁcations.  The  discriminatory  threshold  was  set
at  200,  per the FLEX study,  and  existing  samples  were  re-read  and  classed  as  low  (H-score  < 200)  or  high
(≥200)  EGFR  expression.  PFS  and  OS  were  re-analyzed  based  on  these  new  classiﬁcations.
Results: In the  overall  and  EGFR  wild-type  populations,  erlotinib  provided  a consistent  survival  beneﬁt
versus  placebo.  Hazard  ratios  (HRs)  in the  overall  population  were  similar  between  EGFR  IHC-positive
and  -negative  patients  for median  PFS  (HR 0.68  [95%  conﬁdence  interval  (CI)  0.53–0.86]  and  0.76  [95% CI
0.62–0.93],  respectively)  and  OS  (HR  0.80  [95%  CI 0.62–1.05]  and  0.80 [95%  CI 0.64–1.01]  for  IHC-positive
and  IHC-negative,  respectively).  In  the  EGFR  wild-type  population,  HRs  were  again  similar  between  EGFR
IHC-positive  and  -negative  subpopulations  for PFS  (HR  0.69  [95%  CI 0.51–0.95]  and  0.84 [95% CI 0.63–1.12],
respectively)  and  OS  (HR 0.78  [95%  CI  0.55–1.10]  and  0.76  [95%  CI 0.55–1.05],  respectively).
Conclusions: These  data  suggest  that EGFR IHC  does  not  have  value  as  a marker  to  predict  erlotinib  beneﬁt
nce  s
The Ain  the  ﬁrst-line  maintena
© 2013 
. IntroductionCytotoxic chemotherapy treatment for patients with metastatic
on-small cell lung cancer (NSCLC) has reached a plateau [1].
trategies to further improve outcomes for these patients include
ustomized chemotherapy regimens and the integration of tar-
eted therapy. One of the major targets in lung oncogenesis is
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the epidermal growth factor receptor (EGFR), which belongs to
the ErbB family of transmembrane tyrosine-kinase (TK) receptors.
EGFR moderates the activation of a signaling pathway controlling
cell proliferation, invasion, metastasis and angiogenesis. This path-
way also plays a role in inhibiting apoptosis. Blocking EGFR function
has been proven to be an effective treatment strategy across mul-
tiple tumor types whether by TK inhibitors (TKIs) such as erlotinib
or antibodies such as cetuximab [2–7].
Erlotinib, an orally available EGFR TKI, has proven efﬁcacy
as a second- or third-line treatment for NSCLC patients with
Open access under CC BY-NC-SA license. progressive disease after ﬁrst-line chemotherapy [2], and as
ﬁrst-line therapy in patients whose tumors harbor activating
EGFR mutations [3,4]. The efﬁcacy of erlotinib as mainte-
nance therapy in patients with non-progressive disease following
SA license. 
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rst-line platinum-doublet chemotherapy for NSCLC was  also
emonstrated in the double-blind, randomized, phase III SATURN
tudy (BO18192). Erlotinib-treated patients achieved signiﬁ-
antly longer progression-free survival (PFS) than placebo-treated
atients (p < 0.0001), regardless of clinical characteristics [8]. With
egards to the co-primary endpoint, namely PFS in patients with
igh EGFR protein expression as assessed by immunohistochem-
stry (IHC), PFS was signiﬁcantly longer in patients with EGFR IHC-
ositive tumors who received erlotinib versus placebo (p < 0.0001).
GFR IHC-positive disease was deﬁned in SATURN as any mem-
rane staining in ≥10% of tumor cells. A prospective biomarker
nalysis from this study found that the interaction between treat-
ent and EGFR IHC status was not signiﬁcant for PFS (p = 0.63) or
verall survival (OS; p = 0.52), suggesting no differential effect of
rlotinib between IHC-positive and IHC-negative groups [9].
Cetuximab,  a chimeric monoclonal antibody targeting EGFR, has
lso been investigated in advanced NSCLC. In a major phase III clin-
cal trial, the FLEX study, the investigators demonstrated that the
ddition of ﬁrst-line cetuximab to cisplatin and vinorelbine sig-
iﬁcantly improved OS (p = 0.044) compared with chemotherapy
lone in patients with stage IV NSCLC [6]. In an attempt to increase
he clinical beneﬁt–risk ratio of this combination, the investigators
xamined the expression of EGFR by IHC as a potential predictive
actor [10]. They used the H-score method with magniﬁcation rule,
s previously proposed by Hirsch et al. [11] to deﬁne staining inten-
ity across different categories [12]. A score was assigned to each
atient on a continuous scale of 0–300 with an outcome-based
iscriminatory threshold calculated at 200. Based on this catego-
ization, EGFR IHC-positive status (H-score ≥ 200) was  associated
ith improved OS for patients who received cetuximab, whereas
atients with EGFR IHC-negative status (H-score < 200) had no OS
eneﬁt with cetuximab [10].
We hypothesized that this scoring system with magniﬁcation
ule might help to predict outcomes in patients treated with EGFR
KIs as maintenance therapy. We  therefore re-examined existing
vailable samples from the SATURN study using this alternative
GFR IHC reading and scoring method, to determine whether the
ew classiﬁcation would lead to any correlation between EGFR IHC
tatus and survival outcomes with erlotinib in this setting.
.  Materials and methods
.1.  Study design
Between December 2005 and May  2008, 1949 patients were
creened and received platinum-doublet chemotherapy. A total of
89 patients had non-progressive disease after chemotherapy and
ere suitable for randomization into the SATURN study. Following
tratiﬁcation (according to EGFR IHC status, disease stage, East-
rn Cooperative Oncology Group [ECOG] performance status [PS],
hemotherapy regimen, smoking status and region), patients were
andomized to receive either erlotinib (150 mg/day) or placebo
ntil disease progression or unacceptable toxicity. The SATURN
nclusion/exclusion criteria and methodology are further detailed
n the original manuscript [8]. The study was carried out in accor-
ance with the Declaration of Helsinki and Good Clinical Practice
uidelines. The protocol was approved by local ethics committees
t each investigating center. All patients gave informed written
onsent, both for study participation and the provision of a tumor
ample.
.2. IHC analysesIn  the pre-speciﬁed SATURN study analyses (SATURN protocol-
eﬁned EGFR IHC), EGFR protein expression was assessed by IHC
ith the Dako EGFR PharmDx kit (DakoCytomation, Berkeley, CA).er 82 (2013) 231– 237
Samples were classiﬁed as EGFR IHC positive if ≥10% of the tumor
cells demonstrated membranous staining of any intensity. At the
time of the prospective pre-planned analysis, an exploratory H-
score-based (without magniﬁcation rule) cut-off search was also
undertaken to determine a threshold for patient beneﬁt according
to EGFR IHC expression. All patients seemed to beneﬁt, therefore a
cut-off based on this marker could not be determined (Fig. 1).
The  updated H-score method (EGFR IHC by H-score with mag-
niﬁcation rule), ﬁrst developed in 2003 by Hirsch et al. [11] was
recently adapted for the FLEX study by Pirker et al. [10]. This
method assigns an IHC H-score to each patient on a continuous
scale of 0–300, based on the percentage of cells at different stain-
ing intensities visualized at different magniﬁcations (unlike the
previously used H-score method visualized at one magniﬁcation)
[10]. Membrane staining was scored according to four categories:
0 for ‘no staining’, 1 + for ‘light staining visible only at high mag-
niﬁcation’, 2 + for ‘intermediate staining’ and 3 + for ‘dark staining
of linear membrane, visible even at low magniﬁcation’ as seen in
Supplementary Fig. 1. The percentage of cells at different stain-
ing intensities was determined by visual assessment, with the
score calculated using the formula 1 × (% of 1 + cells) + 2 × (% of
2 + cells) + 3 × (% of 3 + cells) [10]. As per the FLEX analysis, the
outcome-based discriminatory threshold IHC H-score for this anal-
ysis was  set at 200 and existing samples were re-read and scored
according to the above method. Samples were then classiﬁed
as either low (H-score < 200; IHC negative) or high (≥200; IHC
positive) for EGFR protein expression. A secondary analysis was
also carried out using the new reading results with the original
protocol-deﬁned designation of EGFR IHC-positive status as ≥10%
any membrane staining.
Supplementary material related to this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.lungcan.
2013.07.016.
The IHC scoring assessment was  performed by a commercial lab,
Targos Advance (Kassel, Germany). EGFR IHC scoring of all cases
was performed by a senior pathologist. All equivocal cases with
H-score between 150 and 250 and any cases with non-speciﬁc
staining, ﬁxation artifacts or pseudomembranous staining were
scored blinded by a second board-certiﬁed pathologist. All cases
which were found to be discrepant in positive or negative score
were reanalyzed and discussed by both pathologists before a ﬁnal
score was  given.
2.3.  Statistical analysis
PFS  and OS were analyzed in terms of hazard ratios [HRs]
and 95% conﬁdence intervals [CI] by Cox model, with log-rank
p-values to assess signiﬁcance (by EGFR IHC status using the
‘protocol-deﬁned’ and ‘H-score with magniﬁcation rule’ methods).
The p-values for ‘H-score with magniﬁcation rule (200 score cut-
off)’ and H-score with magniﬁcation (10% staining cut-off) were
exploratory in nature, as they were not adjusted for multiple test-
ing.
3. Results
The prospective SATURN EGFR IHC analysis used samples from
370 and 372 patients in the erlotinib and placebo arms, respec-
tively. The current analysis examined existing available samples
from 351 and 361 patients in the erlotinib and placebo arms, respec-
tively.By applying the H-score with magniﬁcation rule using a thresh-
old of 200, we  identiﬁed 303 patients in the high-score, EGFR
IHC-positive group (≥200) and 409 patients in the low-score, EGFR
IHC-negative group (<200). Baseline characteristics were generally
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Fig. 1. Evolution chart using H-s
imilar between the overall SATURN population and the EGFR IHC
ubgroups, however the EGFR IHC-positive group did include more
atients with squamous-cell histology compared with the IHC-
egative group, as already observed in the FLEX study [6] (Table 1).
he patients with EGFR wild-type disease also had similar baseline
haracteristics to the overall population. Of the 189 patients with
GFR wild-type disease in the placebo arm and the 199 patients
ith wild-type disease in the erlotinib arm, 181 and 189 patients,
espectively, had valid H-score with magniﬁcation rule result.
Using  the H-score assessment with the magniﬁcation rule,
he HR in the overall intent-to-treat (ITT) population was  similar
etween patients with EGFR IHC-positive and -negative tumors
or median PFS (HR 0.68 and 0.76, respectively) and median OS
HR 0.80 for both IHC scores), showing little difference in PFS
r OS between patients with IHC H-score-positive and -negative
able 1
aseline characteristics in the overall population and EGFR wild-type population versus t
N (%) Overall SATURN population EGFR wild-type po
Characteristic Erlotinib
(n = 438)
Placebo
(n  = 451)
Erlotinib
(n  = 199)
P
(
Gender
Male 321 (73) 338 (75) 161 (81) 1
Female  117 (27) 113 (25) 38 (19) 3
Median  age, years 60 60 60 5
(range)  (33–83) (30–81) (35–83) (
Disease  stage
IIIB  116 (26) 109  (24) 55 (28) 4
IV  322 (74) 342 (76) 144 (72) 1
ECOG  PS
0  135 (31) 145 (32) 64 (32) 6
1  303 (69) 306 (68) 135 (68) 1
Histology
Adenocarcinoma/ 205 (47) 198 (44) 83 (42) 7
Bronchoalveolar carcinoma
Squamous-cell  carcinoma 166 (38) 194 (43) 95 (48) 9
Other  67 (15) 59 (13) 21 (11) 1
Smoking  status
Current  smoker 239 (55) 254 (56) 116 (58) 1
Former  smoker 122 (28) 122 (27) 58 (29) 5
Never  smoker 77 (18) 75 (17) 25 (13) 2ane H-score
magniﬁcation rule not applied).
status.  Despite the difference in categorization, the HRs for median
PFS and median OS comparisons were similar between the two
scoring methods (Table 2). In the unselected population, erlotinib
demonstrated signiﬁcantly prolonged PFS compared with placebo
in patients with high EGFR IHC status regardless of the method used
(p < 0.0001 for protocol-deﬁned method and exploratory p = 0.0010
for H-score with magniﬁcation rule).
In the EGFR wild-type (WT) population, erlotinib provided a con-
sistent survival beneﬁt versus placebo, regardless of IHC scoring
method used (Table 2). The PFS for the population with protocol-
deﬁned IHC-positive disease was  12.1 weeks for the erlotinib arm
compared with 10.4 weeks for the placebo arm (HR 0.79, p = 0.0336;
Fig. 2a). For patients with IHC-negative disease, PFS was  10.9 weeks
versus 7.1 weeks (HR 0.65, p = 0.1146) for erlotinib and placebo,
respectively. When assessed by the H-score with magniﬁcation
he EGFR IHC high and low subgroups.
pulation EGFR IHC low (H-score
<200)  population
EGFR IHC high (H-score
≥200)  population
lacebo
n  = 189)
Erlotinib
(n  = 205)
Placebo
(n  = 204)
Erlotinib
(n  = 146)
Placebo
(n  = 157)
50 (79) 148 (72) 152 (75) 108 (74) 113 (72)
9 (21) 57 (28) 52 (25) 38 (26) 44 (28)
9 59.2 58.9 59.9 60.6
30–76) (33–81) (33–81) (35–83) (30–77)
7 (25) 52 (25) 48 (24) 39 (27) 40 (25)
42 (75) 153 (75) 156 (76) 107 (73) 117 (75)
9 (37) 61 (30) 68 (33) 50 (34) 49 (31)
20 (63) 144 (70) 136 (67) 96 (66) 108 (69)
6 (40) 113 (55) 96 (47) 56 (38) 61 (39)
6 (51) 60 (29) 78 (38) 73 (50) 77 (49)
7 (9) 32 (16) 30 (15) 17 (12) 19 (12)
10 (58) 113 (55) 109 (53) 75 (51) 88 (56)
7 (30) 58 (28) 60 (29) 44 (30) 41 (26)
2 (12) 34 (17) 35 (17) 27 (18) 28 (18)
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Table 2
Analysis of PFS and OS by EGFR IHC status according to different scoring methods.
SATURN
protocol-deﬁned
EGFR IHC +
SATURN
protocol-deﬁned
EGFR IHC–
EGFR IHC by
H-score  ≥200
(high)
EGFR IHC by
H-score  <200 (low)
EGFR IHC by
H-score  ≥10%
EGFR IHC by
H-score  <10%
ITT population
n  Erlotinib: 308 Erlotinib: 62 Erlotinib: 146 Erlotinib: 205 Erlotinib: 267 Erlotinib: 84
Placebo:  313 Placebo: 59 Placebo: 157 Placebo: 204 Placebo: 287 Placebo: 74
PFS,  HR (95% CI) 0.69 (0.58–0.82) 0.77 (0.51–1.14) 0.68 (0.53–0.86) 0.76 (0.62–0.93) 0.71 (0.59–0.84) 0.79 (0.57–1.10)
p  < 0.0001 p = 0.1768 p = 0.0010 p = 0.0076 p < 0.0001 p = 0.1627
OS,  HR (95% CI) 0.77 (0.64–0.93) 0.91 (0.59–1.38) 0.80 (0.62–1.05) 0.80 (0.64–1.01) 0.78 (0.64–0.96) 0.85 (0.60–1.22)
p  = 0.0063 p  = 0.6482 p  = 0.1099 p  = 0.0639 p = 0.0161 p = 0.3901
EGFR  WT population
n  Erlotinib: 170 Erlotinib: 28 Erlotinib: 86 Erlotinib: 103 Erlotinib: 147 Erlotinib: 42
Placebo:  157 Placebo: 27 Placebo: 84 Placebo: 97 Placebo: 144 Placebo: 37
PFS,  HR (95% CI) 0.79 (0.63–0.99) 0.65 (0.37–1.13) 0.69 (0.51–0.95) 0.84 (0.63–1.12) 0.78 (0.62–0.99) 0.69 (0.44–1.10)
p  = 0.0336 p  = 0.1146 p  = 0.0188 p  = 0.2166 p  = 0.0400 p  = 0.1126
OS,  HR (95% CI) 0.77 (0.60–0.99) 0.64 (0.35–1.20) 0.78 (0.55–1.10) 0.76 (0.55–1.05) 0.78 (0.60–1.02) 0.72 (0.43–1.19)
p  = 0.0402 p = 0.1608 p = 0.1563 p = 0.0964 p = 0.0698 p = 0.2004
Note: HR < 1 is in favor of erlotinib; all p-values are by log-rank test; not adjusted for multiple testing.
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Fig. 2. (a) PFS in the EGFR WT population according to protocol-deﬁned EGFR IHC status. (b) PFS in the EGFR WT population according to EGFR IHC H-score with magniﬁcation.
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vig. 3. (a) OS in the EGFR WT population according to protocol-deﬁned EGFR IHC sta
ule, PFS for patients with IHC-positive disease (score ≥ 200) was
2.1 weeks in the erlotinib arm and 6.3 weeks in the placebo arm
HR 0.69, exploratory p = 0.0188; Fig. 2b). PFS for patients with IHC-
egative disease (H-score < 200) was 12.0 weeks in the erlotinib
rm and 11.3 weeks in the placebo arm (HR 0.84, exploratory
 = 0.2166; Fig. 2b).
For OS in the EGFR WT  population, the patients with protocol-
eﬁned IHC-positive disease had a signiﬁcant beneﬁt with erlotinib
ersus placebo (HR 0.77, p = 0.0402), while assessment by H-score
ith magniﬁcation rule (≥200) resulted in a HR of 0.78 (exploratory
 = 0.1563) (Fig. 3a and b). Protocol-deﬁned assessment of patients
ith IHC-negative disease resulted in a HR of 0.64 (p = 0.1608) and
hen assessed by H-score with magniﬁcation rule the HR was 0.76
exploratory p = 0.0964).
When the protocol-deﬁned scoring system of ≥10% membrane
taining of any intensity to deﬁne IHC-positive status was applied
o the new readings (meaning the H-score with magniﬁcation rule
eadings were assessed as positive if ≥10% of cells had positive-
taining without giving any weighting to the magniﬁcation used to
isualize the staining), HR values were similar to both the original) OS in the EGFR WT  population according to EGFR IHC H-score with magniﬁcation.
protocol-derived values and the H-score with magniﬁcation values
(Table 2).
4.  Discussion
Maintenance treatment is now a standard therapeutic strategy
in advanced NSCLC, but many challenges still exist, such as iden-
tifying the patients who  derive the most beneﬁt from continuing
anti-cancer treatment until progression. As erlotinib directly tar-
gets EGFR and identiﬁcation of high EGFR protein expression by
IHC was recently shown to be predictive of efﬁcacy with the EGFR
inhibitor cetuximab in advanced NSCLC, we aimed to apply this
test to the cohort of SATURN patients. Re-scoring of EGFR IHC sta-
tus in SATURN by H-score with the magniﬁcation rule found that
erlotinib provided similar beneﬁts in terms of PFS or OS for sub-
sets with high or low EGFR expression, in the overall and EGFR WT
populations. This was despite clear differences in the categorization
of patients by the two different methods into EGFR IHC-positive
or -negative subpopulations, as demonstrated by the number of
236 J.  Mazières et al. / Lung Cancer 82 (2013) 231– 237
F l-deﬁn
f -score
p
n
n
b
H
u
c
r
p
m
e
d
e
t
c
i
t
n
o
a
p
m
b
S
o
E
b
e
b
u
e
t
a
d
a
t
c
t
p
w
a
t
c
n
a
s
rig. 4. Two representative cases, which were scored positive according the protoco
or  EGFR expression. Image A shows a case stained heterogenous for EGFR with a H
atients in each category (protocol-deﬁned IHC positive n = 621,
egative n = 121; H-score with magniﬁcation rule high n = 303, low
 = 409). Fig. 4 demonstrates samples that were classed positive
y the protocol-deﬁned scoring but were classed negative by the
-score plus magniﬁcation rule method. From the evolution chart
sed in the original IHC analysis (Fig. 1), markedly different out-
omes were not expected; however, the use of the magniﬁcation
ule may  have provided more objective guidance to the reading
athologist.
In both studies, EGFR analysis was performed on pretreat-
ent biopsies, but the possibility cannot be excluded that EGFR
xpression is modiﬁed by induction chemotherapy, as has been
emonstrated for EGFR mutation status [13]. Thus, the level of EGFR
xpression may  have changed from the initial assessment by the
ime erlotinib was administered in the SATURN study, whereas
etuximab was given ﬁrst line in the FLEX study. Moreover, patients
ncluded in the SATURN study were non-progressive after induc-
ion chemotherapy, meaning that chemoresistant patients were
ot taken into account, in contrast to the FLEX study.
It  could be suggested that this negative result is due to a lack
f reproducibility of the method. However, this seems unlikely
s a recent study showed good reproducibility between training
athologists, with a concordance of 76–91% [14].
Lastly, the most probable explanation relies on the use of a
onoclonal antibody in combination with a chemotherapy dou-
let in the FLEX study versus an EGFR TKI as monotherapy in the
ATURN study. The different agents have differences in their mode
f action, with one targeting the internal kinase activity of the
GFR and the other targeting the protein externally by an antibody
locking ligand binding. Therefore, the predictive value of EGFR
xpression could be expected to be different with these agents
ecause of their distinct mechanisms of action. One could spec-
late that EGFR expression could be more likely to predict the
fﬁcacy of antibodies, as part of their anti-tumor effect is mediated
hrough antibody-dependent cellular cytotoxicity, which is directly
ssociated with the presence of EGFR protein [15]. The best pre-
ictive marker for cetuximab remains unknown: KRAS mutations
re known to be associated with cetuximab resistance in colorec-
al cancer, but no reliable markers are currently available for lung
ancer.
The H-score method with magniﬁcation rule used retrospec-
ively in the FLEX study of cetuximab reported an OS beneﬁt in
atients with EGFR IHC-positive tumors but no beneﬁt in patients
ith EGFR IHC-negative disease for cetuximab plus chemother-
py versus chemotherapy alone [10]. However, as the cut-off for
he H-score threshold was data driven, no dedicated trial has been
onducted so far to validate prospectively the H-score method. Of
ote, in the phase III BMS  099 study of cetuximab and ﬁrst-line tax-
ne/carboplatin in NSCLC patients, EGFR expression did not predict
urvival outcomes for cetuximab [16]. When the BMS  099 data was
etrospectively analyzed by the same H-score as used in the FLEXed scoring, but scored negative applying the H-score method with a cut-off of 200
 of 120 and B another case with a H-score of 180.
study,  EGFR expression again did not predict overall survival or
progression-free survival outcomes for cetuximab [17].
For  EGFR TKIs, EGFR mutations have been proven to be the best
biomarker for the prediction of superior efﬁcacy [3,18–20]. The
potential use of EGFR expression as a marker has been widely
investigated, with conﬂicting results. High EGFR expression has
been previously associated with improved response, longer time to
progression and improved survival in NSCLC patients treated with
geﬁtinib [21]. Biomarker analysis of the BR.21 study showed sur-
vival among patients with high EGFR expression was longer in the
erlotinib arm versus the placebo arm, whereas a limited advantage
of erlotinib treatment was seen in patients with EGFR IHC-negative
tumors [22]. These results were the basis for the inclusion of PFS in
patients with EGFR IHC-positive disease as a co-primary endpoint
in SATURN. However, Pérez-Soler et al. reported no correlation
between survival and EGFR expression (p = 0.90) in NSCLC patients
treated with erlotinib in the second-/third-line setting [23]. Addi-
tionally, Murray et al. demonstrated no correlation between EGFR
protein expression and disease control rate in erlotinib-treated
patients when staining for total EGFR or phosphorylated EGFR [24].
For the SATURN study, using a positive threshold of ≥10% mem-
brane staining failed to identify any correlation between EGFR
expression and patient outcomes. Using a different IHC analysis
method (H-score with application of the magniﬁcation rule) in
the present analysis did not change the correlation between EGFR
expression levels and PFS or OS in SATURN. The different results
between these studies suggest that the value of EGFR IHC to pre-
dict clinical outcomes may  vary between different EGFR inhibitors
and across different patient populations and treatment settings.
The  BioLOGUE advisors recently concluded that EGFR IHC sta-
tus was weakly prognostic but not predictive of outcomes with
erlotinib, and noted that inconsistency across trials meant EGFR
IHC was not a suitable biomarker [25]. Assessment of total recep-
tor expression may  not be the most accurate indicator of response
to EGFR TKIs, as EGFR activating mutations are considered to be
more important than EGFR protein expression levels. It has been
suggested that a combination of IHC and ﬂuorescence in situ
hybridization may  provide more suitable analysis [24], but this
method has not yet been investigated in clinical trials. One reason
that previous EGFR IHC studies might not have shown correlations
with treatment response may  be that the majority of diagnostic
antibodies target the external domain of the receptor, while it is
mutations in the internal tyrosine-kinase domain that result in the
increased response to erlotinib. The use of a diagnostic antibody
that targets the internal EGFR domain (such as 5B7) [26] might
result in better prediction of response with erlotinib using IHC.5.  Conclusion
The results of this re-analysis suggest that EGFR IHC does not
accurately predict erlotinib beneﬁt for the overall population or
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